CytoMed's Technologies
CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf"
immunotherapeutics for a wide range of cancers.
CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using
our proprietary technologies for our customers.
CytoMed Therapeutics
Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers.
CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers.
Publications